Epidemiology of Antimicrobial Resistance Among Blood and Respiratory Specimens in the United States Using Genotypic Analysis from a Cloud-Based Population Surveillance Network

Decorative image of the AMR Learning Lounge

Epidemiology of Antimicrobial Resistance Among Blood and Respiratory Specimens in the United States Using Genotypic Analysis from a Cloud-Based Population Surveillance Network 

SUMMARY

bioMérieux pharmacist Tristan Timbrook and team analyzed data from the BIOFIRE® Pneumonia (PN) and BIOFIRE® Blood Culture Identification 2 (BCID2) Panels using BioFire Syndromic Trends, a cloud-based surveillance network software, to determine the prevalence of multi-drug resistant organisms (MDRO) across various US regions. Near real-time characterization of these resistance types is important for the development of local guidelines and outbreak detection, regional benchmarking, and informing national public health initiatives.

FEATURED EXPERTS

Tristan Timbrook, PharmD, Director of Health Economics Outcomes Research, Global Medical Affairs at bioMérieux

GET STARTED

Read about the study in the Open Forum Infectious Diseases article.

Take me there now!

Read time: 18 minutes

We want to hear from you!

Your feedback helps us continue to provide resources and content specific to your needs.

Take Our Poll

Global Solutions

BIOFIRE^® Blood Culture Identification 2 Panel

The BIOFIREBCID2 Panel tests for 43 targets associated with bloodstream infections, including Gram-negative bacteria, Gram-positive bacteria, yeast, and 10 antimicrobial resistance genes – all with one test and with results available in about an hour from positive blood culture.

Learn More

Us Solutions

BioFire^® Syndromic Trends

BioFire Syndromic Trends (Trend) is a software feature from BioFire that provides local and regional pathogen circulation trends on demand. Users can view pathogen trends for their lab as well as regional and national pathogen trends, all of which are created from de-identified data that has been aggregated with other participating institutions’ test data.

Learn More

PUBLISHED BY

IDSA Open Forum Infectious Diseases
June 17, 2022